ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Multivariate patterns of plasma biomarkers predict region-specific Alzheimer's pathology and cognitive decline across independent cohorts.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionAlzheimer's disease (AD) is characterized by the progressive accumulation of amyloid-beta (Aβ) plaques, tau tangles, and neurodegeneration (ATN framework). While neuroimaging detects these changes, it is costly and not widely accessible. Blood-based biomarkers offer scalable alternatives for early detection.
methodsWe integrated plasma biomarkers, neuroimaging, and cognitive data from two large cohorts. We examined multivariate patterns of plasma Aβ42/Aβ40, phosphorylated tau (p-tau) 217, p-tau181, neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) that predict amyloid, tau, neurodegeneration, and memory decline.
resultsSpecific plasma biomarker combinations predicted amyloid burden in the precuneus, tau in the entorhinal cortex, hippocampal atrophy, and memory decline. Models trained in one cohort accurately predicted outcomes in the other, confirming cross-cohort generalizability. DISCUSSION: Distinct plasma signatures reflect underlying AD pathways, supporting the use of blood-based biomarkers as cost-effective, noninvasive tools for early detection, disease monitoring, and individualized risk profiling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.